Clinical trial
A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321
NCT00354861 · Immutep S.A.S., Industry · Completed
Key facts
| NCT number | NCT00354861 |
|---|---|
| Title | A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321 |
| Official title | A Phase I, Single-Blind Study to Determine the Safety, Tolerability and Pharmacodynamic Profiles of a Hepatitis B Antigen Combined With IMP321 Versus the Hepatitis B Antigen Alone and a Reference Vaccine in Healthy Young Male Volunteers |
| Lead sponsor | Immutep S.A.S., Industry |
| Collaborators | SGS Aster-Cephac (CRO) |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological |
| Interventions | hepatitis B antigen (without alum) plus IMP321, hepatitis B antigen alone (without alum), Engerix B |
| Enrollment | 48 |
| Start date | May 1, 2005 |
| Primary completion | Nov 1, 2005 |
| Completion | Feb 1, 2006 |
| First posted | Jul 20, 2006 |
| Last update posted | Apr 25, 2008 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: